Dermatology Times: New Research Highlights Zabalafin Hydrogel’s Novel Multitargeted Approach to AD Treatment

News

Dermatology Times: New Research Highlights Zabalafin Hydrogel’s Novel Multitargeted Approach to AD Treatment by Marie Bosslett NEWS PROVIDED BY Alphyn Biologics July 2, 2025 A new paper highlights Alphyn Biologics’ Zabalafin Hydrogel as a promising multitarget therapy for atopic dermatitis, addressing inflammation, itch, and bacterial complications. Read the Dermatology Times article here. CONTACTS   Corporate: Neal…

Alphyn’s Zabalafin Hydrogel for Atopic Dermatitis Highlighted in Leading Peer-Reviewed Journal

Press Release

Alphyn’s Zabalafin Hydrogel for Atopic Dermatitis Highlighted in Leading Peer-Reviewed Journal NEWS PROVIDED BY Alphyn Biologics Jul 01, 2025, 07:30 ET Expert dermatologist panel creates new atopic dermatitis (AD) algorithm (stepped diagnosis and treatment recommendations) emphasizing need for therapeutics that address AD’s intense itch, inflammation, and the AD disease stages of Staphylococcus aureus (Staph) colonization…

2025 European Society for Pediatric Dermatology (EPSD) Poster Presentation: Phase 2 trial of topical drug zabalafin treating mild to moderate atopic dermatitis

Clinical Presentations

2025 European Society for Pediatric Dermatology (EPSD) Poster Presentation: Phase 2 trial of topical drug zabalafin treating mild to moderate atopic dermatitis, starting with infection in children and adults NEWS PROVIDED BY Alphyn Biologics May 29, 2025, 19:30 ET CONTACTS   Corporate: Neal Koller nkoller@alphynbiologics.com (410) 690-8687   Media: Susan Thomas susan@endpointcommunications.net (619) 540-9195

Patient Care Online: Alphyn Biologics Initiates Phase 2b Trial of Botanical Drug for Atopic Dermatitis

News

Patient Care Online: Alphyn Biologics Initiates Phase 2b Trial of Botanical Drug for Atopic Dermatitis by Grace Halsey NEWS PROVIDED BY Alphyn Biologics April 8, 2025 Alphyn Biologics has begun patient dosing in its global CLEAR-AD1 phase 2b clinical trial evaluating zabalafin hydrogel for treatment of atopic dermatitis (AD). The randomized, double-blind, vehicle-controlled study is…